Reuters logo
BRIEF-Johnson & Johnson's Janssen says new results from second phase 3 study show significant efficacy of guselkumab
March 3, 2017 / 12:47 PM / 7 months ago

BRIEF-Johnson & Johnson's Janssen says new results from second phase 3 study show significant efficacy of guselkumab

March 3 (Reuters) - Johnson & Johnson

* New results from second phase 3 study show significant efficacy of guselkumab and superiority versus Humira® in treatment of moderate to severe plaque psoriasis

* Janssen Research - Additional phase 3 study data show significant efficacy of guselkumab in patients experiencing inadequate response to STELARA

* Janssen Research & Development, LLC - In VOYAGE 2 study, co-primary endpoints were met at week 16

* Janssen Research & Development- Through week 28, serious aes were reported in 3.6% of patients receiving guselkumab, 3.6% of patients receiving adalimumab

* Janssen Research & Development- Through week 28, three serious infections each were reported in guselkumab and adalimumab groups

* Janssen-Through week 28, active comparator period, 58.3% of patients receiving guselkumab, 62.9% of patients receiving adalimumab reported at least 1 ae

* Janssen- One malignancy of prostate cancer in guselkumab group, two non-melanoma skin cancers were reported through week 28

* Janssen - Guselkumab also demonstrated superiority across major secondary endpoints in comparisons with ustekinumab in navigate study

* Janssen - Through week 60, aes were reported in 64.4% of patients receiving guselkumab and 55.6% of patients receiving ustekinumab in navigate study

* Janssen - Through week 60, in navigate study, a serious infection occurred in one patient receiving guselkumab

* Janssen - Through week 60 in navigate study, serious aes reported in 6.7% of patients receiving guselkumab and 4.5% in patients treated with ustekinumab

* Janssen - Through week 60 in navigate study, serious aes reported included three myocardial infarctions and two malignancies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below